Autolus Therapeutics Q2 2025 Earnings Report

Autolus Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.23
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Autolus Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $12.92 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Autolus Therapeutics Announcement Details

• Quarter: Q2 2025
• Date: 8/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation programmed T cell therapies for the treatment of cancer. The company’s proprietary CAR T cell platform leverages advanced gene editing and synthetic biology to create T cells with enhanced targeting, safety switches and controllable activity. Its lead programs focus on haematological malignancies, including acute lymphoblastic leukemia and non-Hodgkin lymphoma, with several candidates in ongoing Phase 1 and Phase 2 clinical trials.

Founded in 2014 by a team of immunologists and cell therapy pioneers from University College London and the University of Oxford, Autolus has rapidly built a robust pipeline of autologous T cell products. Key assets feature modular receptor designs and split signaling pathways aimed at improving durability of response and reducing off-tumor toxicity. In addition to its lead CD19- and CD22-targeting therapies, the company is advancing dual-targeted approaches and bispecific constructs intended to address antigen escape and broaden therapeutic applicability.

Headquartered in London, Autolus operates research and development facilities in the United Kingdom and the United States, including a state-of-the-art cell engineering and manufacturing center in Pennsylvania. This transatlantic footprint supports both early-stage discovery work and late-stage clinical manufacturing under current good manufacturing practice (cGMP). The company collaborates with academic institutions and clinical centers of excellence across Europe and North America to conduct multi-site trials and accelerate patient access.

Under the leadership of Chief Executive Officer Dr. Christian Itin and an executive team with deep expertise in cell therapy development and commercial operations, Autolus is focused on delivering innovative T cell medicines to patients with high-unmet-need cancers. The company’s strategic priorities include advancing its clinical portfolio, scaling manufacturing capabilities and establishing global partnerships to expand the reach of its modular CAR T technology.